The effect of compliance and continuity in the treatment of diabetes to its cost in Turkey was discussed at the meeting held in TEPAV.
On November 21, with the support of Lilly Pharmaceuticals and the IQVIA Institute, key stakeholders in diabetes management came together at TEPAV.
In the world and in Turkey, the place of diabetes on the global agenda as well as its economic burden is increasing rapidly. Maintaining compliance and continuity in treatment is one of the important factors affecting the cost of diabetes. On 21 November, TEPAV Innovation Studies Program Director Selin Arslanhan Memiş, Lilly Turkey General Manager Daniel Lucas, Chairman of the Turkish Health Institutions (TÜSEB) Prof.Dr. Fahrettin Keleşemur and Vice-Chairman of the Health, Family, Labor and Social Affairs Commission of the Grand National Assembly of Turkey Celil Göçer made opening speeches. Then Prof. Dr. Simten Malhan gave a talk entitled "How Shall We Look at the Cost of Diabetes in Turkey?" and the IQVIA Institute presented a report on "Improvement of Compliance and Continuity in the Treatment of Type-2 Diabetes in Turkey".
On the report announced at the meeting, it was emphasized that there are more than 6.3 million people living in Turkey with type 2 diabetes, and that this is expected to reach 11.8 million by 2035. The opportunities existing for the improvement of compliance and continuity of treatment against the increasing burden of diabetes were addressed. It was underlined that patients with type 2 diabetes who have poor compliance and continuity of treatment have a 9% risk of heart attack, a 8% risk of a stroke, a 10% risk of amputation and a 30% risk of blindness. The avoidable costs of low compliance and continuity in the treatment of type 2 diabetes are estimated to cost 1.26 billion TL each year for the next decade.
You may access the report from here.
